MAY 2015 ARTICLE LIST >>
PharmaTutor (May- 2015)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 5)
Received On: 10/01/2015; Accepted On: 02/03/2015; Published On: 01/05/2015
AUTHORS: Mohammad Asif
Department of Pharmacy, GRD (PG) Institute of Management & Technology,
Dehradun, Uttarakhand, India
aasif321@gmail.com
ABSTRACT: The reappearance of tuberculosis and the rush of multidrug-resistant clinical isolates of Mycobacterium tuberculosis have reaffirmed tuberculosis as a key public health concern. Describe findings on the pharmacological status of Benzothiazinones as new agents that are being developed as antitubercular drugs. Benzothiazinones act by targeting the enzymes responsible for the formation of arabinans that are essential parts of the cell wall. In view of their novel mechanism of action, these drugs appear promising as anti-TB drugs and considered to be promising candidates for future development.
How to cite this article: M Asif; An overview on Benzothiazinone analogs as Antitubercular Drugs; PharmaTutor; 2015; 3(5); 15-18
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Asif M, Singh A, Lakshmayya; The development of structurally different new antitubercular molecules containing pyridazine ring system. Chronicle of Young Scientist; 2013, 4(1), 1-8.
2. Asif M, Siddiqui AA, Husain A; Quinolone derivatives as antitubercular drugs. Med Chem Res; 2013, 22(3), 1029-1042.
3. Asif M.; Rifampin and Their Analogs: A Development of Antitubercular Drugs. World J Org Chem; 2013, 1(2), 14-19.
4. Asif M.; Study of clinically used and recently developed antimycobacterial agents; Orien Pharm & Experi Med; 2012; 12(1); 15–34.
5. Biavaa M, Porrettaa GC, Deiddab D, Pompeib R.; New Trends in Development of Antimycobacterial Compounds; Infectious Disorders-Drug Targets; 2006; 6(2); 159-172.
6. Makarov V, Manina G, Mikusova K, Möllmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, et al; Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis; Science; 2009; 324; 801–804.
7. Pasca MR, Degiacomi, G Ribeiro AL, Zara, F, De Mori P, Heym B, Mirrione M, Brerra R, Pagani L, Pucillo L, et al; Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother; 2010, 54(4), 1616–1618.
8. Mikusová K, Huang H, Yagi T, Holsters M, Vereecke D, D’Haeze W, Scherman MS, Brennan PJ, McNeil MR, Crick DC; Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose; J. Bacteriol; 2005; 187(23); 8020–8025.
9. Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, Makarov V, Cole ST, Johnsson K; Benzothiazinones: Prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis; J Am Chem Soc; 2010; 132(39); 13663–13665.
10. Manina G, Bellinzoni M, Pasca MR, Neres J, Milano A, Ribeiro AL, Buroni S, Skovierová H, Dianišková P, Mikušová K, et al; Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance; Mol Microbiol; 2010; 77(5); 1172–1185.
11. Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA, et al; Towards a new combination therapy for tuberculosis with next generation benzothiazinones; EMBO Mol. Med.; 2014; 6(3); 372–383.
12. Palomino JC, Martin A; Drug Resistance Mechanisms in Mycobacterium tuberculosis; Antibiotics; 2014; 3(3); 317-340.
13. Asif M; Study of currently used antimycobacterials, their analogoues and recently developed agents; Indian drugs; 2012; 49(7); 5-19.
14. Asif M. A Review of antimycobacterial drugs in development. Mini Rev Med Chem; 2012, 12(13), 1404-1418.
15. Barry CE III; Unorthodox approach to the development of a new antituberculosis therapy; N Engl J Med; 2009; 360; 2466–2467.
.png)
